Abstract
Antithrombin (AT, previously named AT III) is the major physiological inhibitor of blood coagulation. It inactivates mainly thrombin, but also other activated factors, such as activated factor X (factor Xa). Heparin accelerates the reaction between AT and thrombin and AT is also called ‘heparin cofactor’1,2.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abildgaard U. Antithrombin and related inhibitors of coagulation. In: Poller L, ed. Recent advances in blood coagulation. Edinburgh: Churchill Livingstone, 1981; 151.
Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsch J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: basic principles and clinical practice. Philadelphia: Lippincott, 1994; 837–860.
Handeland GF, Abildgaard U, Aasen AO. Simplified assay for antithrombin III activity using chromogenic peptide substrate. Manual and automated method. Scand J Haematol 1983; 31: 427–436.
Odegard OR, Abildgaard U. Antithrombin III: critical review of assay methods. Signification of variations in health and disease. Haemostasis 1978; 7: 127–134.
Conard J, Horellou MH, Bara L. Bovine or human thrombin in antithrombin III (AT III) amidolytic assays. Thromb Haemostas 1985; 54: 25.
Friberger P, Egeberg N, Holmer E, Hellgren M, Blombäck M. Antithrombin assay. The use of human or bovine thrombin and the observation of a second heparin cofactor. Thromb Res 1982; 25: 433–436.
Conard J. Automation of antithrombin III. Methods on routinely available instruments. Sem Thromb Haemostas 1983; 9: 263–267.
Odegard OR, Rosenlund B, Ervik E. Automated antithrombin III assay with a centrifugal analyzer. Haemostasis 1978; 7: 202–209.
Demers D, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, Ofosu FA, Fernandez-Rachubinski F, and rew M, Hirsch J, Ginsberg JS. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemostas 1993; 69: 231–235.
Parvez Z, Fareed J, Argawal P, Messmore HI, Moncada R. Laser nephelometric quantitation of antithrombin III (AT III). Thromb Res 1981; 24: 367–37712.
Peters M, Jansen E, Ten Cate JW, Kahle LH, Ockelford P, Breederveld C. Neonatal antithrombin III. Br J Haematol 1984; 58: 579–587.
Teger-Nilsson AC. Antithrombin in infancy and childhood. Acta Paediatr Scand 1975; 64: 624–628.
Weenink GH, Treffers PE, Kahle LH, Ten Cate JW. Antithrombin III in normal pregnancy. Thromb Res 1982; 26: 281–287.
Meade T, Dyer S, Howard DJ, Imeson JD, Stirling Y Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1990; 74: 77–81.
Tait RC, Walker ID, Davidson JF, Islam SIA, Mitchell R. Antithrombin III activity in healthy blood donors: age and sex related changes and the prevalence of asymptomatic deficiency. Br J Haematol 1990; 75: 141–142.
Thaler E, Lechner K. Antithrombin deficiency and thromboembolism. In: Prentice CRM, ed. Clinics in haematology. London: Saunders, 1981; 369–390.
Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, Jochmans K, Perry DJ, Okajima K, Thein SL, Emmerich J. Antithrombin mutation database: 2nd (1997) update. Thromb Haemostas 1997; 77: 197–211.
Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin HI deficiency: review of 404 cases. Thromb Haemostas 1987; 58: 1094.
Sas G, Pepper DS, Cash JD. Further investigations on antithrombin III in the plasma of patients with the abnormality antithrombin ‘Budapest’. Thromb Diathes Haemorrh 1975; 33: 564–572.
Krudler JW, Strebus AF, Meinders AE, Briet E. Anticoagulant effect of unfractioned heparin in antithrombin-depleted plasma in vitro. Haemostasis 1996; 26: 85–89.
Lechner K, Kyrle PA. Antithrombin III concentrates. Are they clinically useful? Thromb Haemostas 1995; 73: 340–348.
Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemostas 1990; 63: 319–320.
Beresford CH. Antithrombin III deficiency. Blood 1998; 2: 239–250.
Francis ChW, Pellegrini VD Jr, Stulberg BN, Miller ML, Marder VJ. Prevention of venous thrombosis after total knee arthroplasty. J Bone Joint Surg 1990; 72A: 976–982.
Conard J, Samama M, Basdevant A, Guy-Grand B, de Lignieres B. Differential AT III response to oral and parenteral administration of 17β-estradiol. Thromb Haemostas 1983; 49: 252.
Caine YG, Bauer KA, Barzegar S, Ten Cate H, Sacks FM, Waish BW, Schiff I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemostas 1992; 68: 392–395.
Scarabin PY, Alhenec-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach A. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071–3078.
Bounameaux H, Duckert F, Walter M, Bounameaux Y. The determination of antithrombin III. Comparison of six methods. Effect of oral contraceptive therapy. Thromb Haemostas 1978; 39: 607–615.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Conard, J. (1999). Antithrombin activity and antigen. In: Jespersen, J., Bertina, R.M., Haverkate, F. (eds) Laboratory Techniques in Thrombosis — a Manual. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4722-4_13
Download citation
DOI: https://doi.org/10.1007/978-94-011-4722-4_13
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-6472-6
Online ISBN: 978-94-011-4722-4
eBook Packages: Springer Book Archive